Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 2.83
XOMA's Cash to Debt is ranked higher than
63% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. XOMA: 2.83 )
XOMA' s 10-Year Cash to Debt Range
Min: 0.08   Max: 68.89
Current: 2.83

0.08
68.89
Equity to Asset -0.03
XOMA's Equity to Asset is ranked lower than
51% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. XOMA: -0.03 )
XOMA' s 10-Year Equity to Asset Range
Min: -0.6   Max: 0.7
Current: -0.03

-0.6
0.7
F-Score: 4
Z-Score: -11.34
M-Score: -3.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -164.18
XOMA's Operating margin (%) is ranked higher than
65% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. XOMA: -164.18 )
XOMA' s 10-Year Operating margin (%) Range
Min: -2191.67   Max: 13.17
Current: -164.18

-2191.67
13.17
Net-margin (%) -349.94
XOMA's Net-margin (%) is ranked higher than
58% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. XOMA: -349.94 )
XOMA' s 10-Year Net-margin (%) Range
Min: -2153.94   Max: 14.89
Current: -349.94

-2153.94
14.89
ROA (%) -92.04
XOMA's ROA (%) is ranked higher than
52% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. XOMA: -92.04 )
XOMA' s 10-Year ROA (%) Range
Min: -170.65   Max: 3.83
Current: -92.04

-170.65
3.83
ROC (Joel Greenblatt) (%) -901.56
XOMA's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. XOMA: -901.56 )
XOMA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1221.62   Max: 63.94
Current: -901.56

-1221.62
63.94
Revenue Growth (%) -39.00
XOMA's Revenue Growth (%) is ranked higher than
59% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. XOMA: -39.00 )
XOMA' s 10-Year Revenue Growth (%) Range
Min: -60.9   Max: 147.7
Current: -39

-60.9
147.7
EBITDA Growth (%) -26.40
XOMA's EBITDA Growth (%) is ranked higher than
60% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. XOMA: -26.40 )
XOMA' s 10-Year EBITDA Growth (%) Range
Min: -39.7   Max: 31.1
Current: -26.4

-39.7
31.1
EPS Growth (%) -27.10
XOMA's EPS Growth (%) is ranked higher than
63% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. XOMA: -27.10 )
XOMA' s 10-Year EPS Growth (%) Range
Min: -53   Max: 36.5
Current: -27.1

-53
36.5
» XOMA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

XOMA Guru Trades in Q3 2012

Jim Simons Sold Out
» More
Q2 2013

XOMA Guru Trades in Q2 2013

Jim Simons 59,595 sh (New)
» More
Q3 2013

XOMA Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q4 2013

XOMA Guru Trades in Q4 2013

Paul Tudor Jones 20,425 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with XOMA



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 10.40
XOMA's P/S is ranked higher than
52% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. XOMA: 10.40 )
XOMA' s 10-Year P/S Range
Min: 0.55   Max: 63.23
Current: 10.4

0.55
63.23
EV-to-EBIT 0.50
XOMA's EV-to-EBIT is ranked higher than
94% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. XOMA: 0.50 )
XOMA' s 10-Year EV-to-EBIT Range
Min: 4.6   Max: 11.4
Current: 0.5

4.6
11.4

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.80
XOMA's Price/Median PS Value is ranked lower than
56% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. XOMA: 1.80 )
XOMA' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 15.9
Current: 1.8

0.1
15.9
Earnings Yield (Greenblatt) 205.60
XOMA's Earnings Yield (Greenblatt) is ranked higher than
91% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. XOMA: 205.60 )
XOMA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 8.8   Max: 220.1
Current: 205.6

8.8
220.1
Forward Rate of Return (Yacktman) -27.87
XOMA's Forward Rate of Return (Yacktman) is ranked higher than
67% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. XOMA: -27.87 )
XOMA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -83.3   Max: -44
Current: -27.87

-83.3
-44

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:X0M.Germany
XOMA Corp is a biopharmaceutical company, which is engaged in the discovery, development and manufacture of therapeutic antibodies and other agents designed to treat inflammatory, autoimmune, infectious and oncological diseases. The company builds a product pipeline that includes multiple proprietary and collaborative development programs. Its proprietary preclinical pipeline includes classes of antibodies that activate, sensitize, or deactivate the insulin receptor in vivo, that have been named as XMet. This portfolio of antibodies represents potential new therapeutic approaches to the treatment of diabetes and several diseases that involve insulin, which it believe may be orphan drug opportunities. Its main product candidate is XOMA 052, a potent monoclonal antibody with the potential to improve the treatment of patients with a number of diseases in which inflammation is either the cause or plays a considerable role. The company receives royalties on approved products, RAPTIVA, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis, LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration, and the Company no longer receives royalties on sales of CIMZIA. XOMA has granted more than 60 licenses to biotechnology and pharmaceutical companies to use the Company's patented and proprietary technologies relating to bacterial expression of recombinant pharmaceutical products.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide